-
2024-517965-18-00
4
2021-11-11
Advanced NSCLC with common EGFR-Mutation
-
2023-510307-22-00
1
2021-09-24
Advanced head and neck cancer
-
2024-514473-21-00
5
2021-06-21
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
-
2023-509635-89-00
9
2021-06-01
DIPSS-Intermediate or High Risk Myelofibrosis
-
2023-505615-21-00
5
2021-04-28
Muscle Invasive Bladder Cancer
-
2024-510620-39-00
5
2021-04-19
Advanced RCC with clear cell component
-
2023-509120-17-00
5
2021-04-12
Myelofibrosis
-
2022-502705-15-00
5
2021-03-08
High-risk muscle-invasive bladder cancer
-
2022-502606-33-00
5
2021-02-26
Patients with histologically or cytologically documented non-squamous
-
2023-509516-28-00
4
2021-02-22
Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col
-
2024-513252-15-00
4
2021-01-28
IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
-
2022-502841-91-00
5
2020-08-12
Crohn’s Disease
-
2023-504718-31-00
10
2019-10-19
Moderately to Severely Active Ulcerative Colitis
-
2024-512667-31-00
5
2019-04-23
Main cohort: Patients with unresected Stage I/II, lymph-node negative
-
2023-509834-20-00
4
2019-03-13
untreated FLT3-mutated Acute Myeloid Leukemia
-
2024-511365-11-00
5
2018-11-27
Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
-
2024-515783-31-00
5
2018-08-24
Newly Diagnosed Multiple Myeloma
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-504951-29-00
5
2017-07-27
Chron's Disease
-
2023-505509-18-00
5
2017-07-12
mature aggressive B-cell lymphoma and leukemia in children and adolesc
-
2023-505981-26-00
5
2015-11-20
Non−Small Cell Lung Cancer
-
2024-515619-23-00
4
2015-06-29
essential thrombocythemia
-
2024-518841-12-00
9
2025-03-25
HER2 positive resectable esophagogastric adenocarcinoma